



# HHS Public Access

Author manuscript

Cell Rep. Author manuscript; available in PMC 2020 April 16.

Published in final edited form as:

Cell Rep. 2020 March 17; 30(11): 3663–3670.e5. doi:10.1016/j.celrep.2020.02.081.

## The *Borrelia burgdorferi* VlsE Lipoprotein Prevents Antibody Binding to an Arthritis-Related Surface Antigen

Abdul G. Lone<sup>1</sup>, Troy Bankhead<sup>1,2,\*</sup>

<sup>1</sup>Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, USA

<sup>2</sup>Lead Contact

### SUMMARY

Arp is an immunogenic protein of the Lyme disease spirochete *Borrelia burgdorferi* and contributes to joint inflammation during infection. Despite Arp eliciting a strong humoral response, antibodies fail to clear the infection. Given previous evidence of immune avoidance mediated by the antigenically variable lipoprotein of *B. burgdorferi*, VlsE, we use passive immunization assays to examine whether VlsE protects the pathogen from anti-Arp antibodies. The results show that spirochetes are only able to successfully infect passively immunized mice when VlsE is expressed. Subsequent immunofluorescence assays reveal that VlsE prevents binding of Arp-specific antibodies, thereby providing an explanation for the failure of Arp antisera to clear the infection. The results also show that the shielding effect of VlsE is not universal for all *B. burgdorferi* cell-surface antigens. The findings reported here represent a direct demonstration of VlsE-mediated protection of a specific *B. burgdorferi* surface antigen through a possible epitope-shielding mechanism.

### In Brief

Lone and Bankhead report that the antigenically variable VlsE protein of the Lyme disease agent *Borrelia burgdorferi* can prevent antibody binding to a surface antigen of the pathogen. They show that protection is likely via an epitope-shielding mechanism, thus expanding the current role of VlsE in immune evasion.

### Graphical Abstract

---

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

\*Correspondence: [tbankhead@wsu.edu](mailto:tbankhead@wsu.edu).

#### AUTHOR CONTRIBUTIONS


Conceptualization, A.G.L. and T.B.; Methodology, A.G.L. and T.B.; Investigation, A.G.L.; Validation, A.G.L.; Formal Analysis, A.G.L. and T.B.; Writing – Original Draft, A.G.L. and T.B.; Writing – Review & Editing, A.G.L. and T.B.; Visualization, A.G.L. and T.B.; Funding Acquisition, T.B.; Resources, T.B.; Supervision, T.B.

#### DECLARATION OF INTERESTS

The authors declare no competing interests.

#### SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at <https://doi.org/10.1016/j.celrep.2020.02.081>.



## INTRODUCTION

*Borrelia burgdorferi* is a gram-negative, motile flat-wave bacterium that causes Lyme borreliosis (Lyme disease), a tick-transmitted illness of humans and animals. The disease manifests in different clinical forms that range from a local rash termed erythema migrans (in humans) to systemic manifestations of fever and cardiac, neurological, and arthritic complications depending on whether the disease is in the early, disseminating, or late stage of progression (Bouchard et al., 2015; Hyde, 2017; Johnson et al., 2018; Murray and Shapiro, 2010; Stanek et al., 2012; Steere et al., 2016). Lyme disease is the most prevalent tickborne disease in the United States, with nearly 30,000 new cases of the disease reported to the Centers for Disease Control and Prevention (CDC) annually (CDC, 2019; Hinckley et al., 2014). However, the incidence has been suggested to be up to 10-fold higher due to misdiagnosis and failure to report the disease (Kuehn, 2013; Wright et al., 2012).

Among the different clinical manifestations of late-stage Lyme disease in the United States, arthritis is the most common, with nearly 60% of late-stage Lyme disease patients reporting arthritic complications (CDC, 2019). The arthritis-related protein (Arp) of the *B. burgdorferi* B31 strain is a surface lipoprotein encoded by the *bbf01* locus of the 28-kb linear plasmid, lp28-1, and has been shown to be upregulated during host infection (Feng et al., 2000; Liang et al., 2004). Previous studies have demonstrated that Arp is associated with the development of arthritis and contributes to joint swelling in mice (Hove et al., 2014; Imai et al., 2013), and anti-Arp antibodies have been shown to resolve *B.-burgdorferi*-induced

arthritis in severe combined immunodeficiency (SCID) mice (Barthold et al., 2006; Feng et al., 2000; Feng et al., 2003). However, Arp-specific antibodies have been shown to be unable to prevent or clear *B. burgdorferi* infection in mice (Barthold et al., 2006; Feng et al., 2003). This inability of anti-Arp antibodies to clear *B. burgdorferi* infection could be due to epitope shielding by another surface protein capable of immune evasion. In *B. burgdorferi*, VlsE is an antigenically variable cell-surface protein that evades the antibody response by continuously changing its surface epitopes (Norris, 2006), and it could potentially function to shield Arp from antibodies.

The VlsE protein undergoes antigenic variation exclusively during mammalian infection (Norris, 2006; Zhang et al., 1997; Zhang and Norris, 1998) and has been reproducibly shown to be required for *B. burgdorferi* survival and persistence while in the presence of a host humoral response (Bankhead, 2016; Bankhead and Chaconas, 2007; Lawrenz et al., 2004; Rogovskyy and Bankhead, 2013; Rogovskyy et al., 2015). The antigenic variability of VlsE results from nonreciprocal recombination between the *vlsE* gene and 15 silent *vls* cassettes within the *vls* locus located on the same lp28–1 plasmid that carries *arp* (Norris, 2006; Palmer et al., 2009; Verhey et al., 2018a, 2018b; Zhang et al., 1997). Similar to Arp, VlsE has been shown to be upregulated during host infection (Liang et al., 2004). A long-standing question has been how *B. burgdorferi* immune escape is accomplished through sequence variation of this single lipoprotein, despite the presence of a substantial number of additional antigens residing on the bacterial surface. A role for VlsE besides antigenic variation is not currently known, but it has been proposed that the protein might function in other forms of immune evasion (Liang et al., 2002; Philipp et al., 2001). Among the several models that have been suggested, one scenario proposes that VlsE may act as a shield to obscure the epitopes of other surface antigens (Bankhead, 2016).

Given the above information, we hypothesized that VlsE may function to protect Arp from an antibody-mediated immune response. We report here that passive immunization assays involving SCID mice demonstrated that anti-Arp antibodies prevent *B. burgdorferi* infection only in clones that lack expression of VlsE, suggesting immune protection by the antigenically variable lipoprotein. We also performed immunofluorescence experiments to determine whether anti-Arp antibodies bind to Arp-expressing *B. burgdorferi* strains in the presence of VlsE. These experiments confirmed that Arp is indeed protected from Arp-specific antibody binding when VlsE is present, likely via an epitope-shielding mechanism.

## RESULTS

### Generation of a *B. burgdorferi* Clone Capable of Simultaneous Expression of Arp and VlsE

Previous work has provided some evidence of VlsE-mediated protection of *B. burgdorferi* surface antigens against the host antibody immune response (Rogovskyy and Bankhead, 2013, 2014; Rogovskyy et al., 2015), although any surface proteins being directly protected by VlsE had yet to be identified. Despite the inability of Arp antiserum to prevent or clear infection by *B. burgdorferi* in mice (Barthold et al., 2006; Feng et al., 2003), a pilot experiment in our lab demonstrated that a *vlsE*-deletion mutant clone of *B. burgdorferi* could be successfully cleared in infected SCID mice after treatment with anti-Arp antibodies (unpublished data). This preliminary finding was the basis for initiating studies to determine

whether the presence of VlsE allows for evasion of the Arp surface antigen from recognition by anti-Arp antibodies.

Our initial strategy to test this was to treat SCID mice with sera containing anti-Arp antibodies and then challenge mice with *B. burgdorferi* clones expressing or lacking VlsE. For this approach to be successful, it was necessary that our *B. burgdorferi* clone exhibit simultaneous expression of Arp and VlsE prior to murine challenge. Although western blot analysis showed some VlsE surface expression from *in-vitro*-grown wild-type B31-A3 spirochetes similar to a previously published study (Figure 1A; Grimm et al., 2004), no detectable Arp could be observed from this clone (Figure 1B). To achieve either individual or simultaneous expression of Arp and VlsE, we employed a strategy that involved the generation of high-copy expression clones of the *B. burgdorferi* B31-A1 strain that lacks the *arp*- and *vlsE*-resident lp28-1 plasmid (hereafter referred to as A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup>; Elias et al., 2002). This was accomplished by cloning *arp* or *vlsE* into a pBSV2 shuttle vector (Stewart et al., 2001) harboring either a gentamicin (pBSV2g-*arp*) or kanamycin (pBSV2-*vlsE*) resistance gene, respectively, and then transforming the plasmids into A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> cells. Because these genes reside on a high-copy shuttle vector with only their basal promoter sequences intact, the expectation was elevated expression levels of *arp* and *vlsE* that are no longer subjected to regulatory effects.

To ensure that the generated A1 clones (Tables S1 and S2) express and membrane localize Arp (A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup>), VlsE (A1 *arp*<sup>-</sup>/*vlsE*<sup>+</sup>), or both Arp and VlsE (A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup>), western blot analysis was conducted on proteinase-K-treated spirochetes and Triton X-114 extracted spirochete proteins. As expected, immunoblots using anti-Arp or anti-VlsE antibodies confirmed both individual and simultaneous surface expression of the two lipoproteins compared to the parental A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> control (Figures 1C–1F). Western blot analysis utilizing antibodies against the cytosolic BosR protein verified proper phase separation of detergent and aqueous phase proteins (Figure 1G).

Because Arp and VlsE in the A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> strain are expressed from plasmids with different antibiotic resistance markers but identical origins of replication, it was also necessary to determine whether individual bacteria produce the Arp protein to be targeted on their surface. To ascertain Arp expression on individual spirochetes harboring pBSV2g-*arp*, flow cytometric analysis was carried out on the A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> clone and a control strain that harbored the pBSV2g-*arp* plasmid along with the same pBSV2 plasmid found in the A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> clone, except that it lacked the *vlsE* gene. The absence of the *vlsE* gene was necessary due to the potential of VlsE to prevent binding of anti-Arp antibodies during flow cytometric analysis. The results show that although the presence of both plasmids leads to an ~2-fold decrease in the median fluorescence intensity (MFI; 365 versus 172; Figures 1H and S1), Arp is clearly expressed within the population at levels that would allow targeting by anti-Arp antibodies. In comparison to Arp expression, VlsE expression was higher in both A1 *arp*<sup>-</sup>/*vlsE*<sup>+</sup> and A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> (Figure S2); similar to Arp however, VlsE expression was found to be lower in the A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> clone (MFI 681 versus 500). Combined, the above results demonstrate that the combination of both constructs in the A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> clone leads to an increase in the overall expression of Arp or VlsE when compared to the B31-A3 wild-type strain.

Expression of Arp and/or VlsE by the various clones during infection of C3H mice was confirmed by the presence (Figures 1I–1K) or absence (Figure 1L) of serum antibodies against these two proteins. Interestingly, the antibody response to multiple proteins appeared to differ somewhat between sera raised in the presence or absence of VlsE (Figure 1J versus Figure 1K), potentially indicating that VlsE might shield multiple surface antigens. For the remainder of this study, the  $A1 arp^-/vlsE^-$ ,  $A1 arp^+/vlsE^-$ , and  $A1 arp^+/vlsE^+$  clones were utilized to assess the ability of VlsE to provide protection of Arp from antibody recognition. It should also be noted that VlsE antigenic variation cannot occur in these clones due to the lack of the silent cassette region. However, the prediction was that *vlsE* recombination would not be necessary to assess VlsE-mediated immune protection of surface antigens due to the use of passively transferred antibodies.

### **Arp-Specific Antiserum Prevents Infection by *B. burgdorferi* Expressing Arp, but Not by *B. burgdorferi* Expressing Both Arp and VlsE**

To assay whether VlsE has the capacity to protect Arp from anti-Arp antibodies, SCID mice were divided into nine groups. Groups of mice were passively immunized with either sera raised against recombinant Arp, the  $A1 arp^-/vlsE^-$  clone, or non-immune sera and then challenged 16 h later with  $A1 arp^+/vlsE^-$ ,  $A1 arp^+/vlsE^+$ , or  $A1 arp^-/vlsE^-$  spirochetes. Blood samples were collected at 7 days post-inoculation, and ear, heart, bladder, and joint tissue samples were harvested at 28 days post-inoculation. All samples were cultured individually under appropriate antibiotic selection, and the presence of the *arp* and/or *vlsE*-harboring shuttle plasmids in recovered spirochetes was verified via PCR analysis. As expected, the results showed that  $A1 arp^-/vlsE^-$  antisera prevented infection of mice challenged by either  $A1 arp^-/vlsE^-$  or  $A1 arp^+/vlsE^-$  clones, and Arp antisera were unable to prevent infection by  $A1 arp^-/vlsE^-$  spirochetes lacking Arp (Tables 1 and S3). However, Arp antisera were able to prevent infection by the  $A1 arp^+/vlsE^-$  clone in a statistically significant number of mice ( $p < 0.05$ ), but it was unable to prevent the  $A1 arp^+/vlsE^+$  clone from infecting mice (Tables 1 and S3). Because the difference between the  $A1 arp^+/vlsE^-$  and  $A1 arp^+/vlsE^+$  clones is the production of VlsE, this finding strongly suggests that the presence of VlsE protects the Arp lipoprotein from host antibody recognition. These results also demonstrate successful prevention of challenge of Arp-expressing spirochetes by Arp antisera, suggesting that past failures were at least partially due to a lack of Arp expression by cultivated wild-type clones prior to challenge of mice. Interestingly, the  $A1 arp^+/vlsE^+$  clone was mostly incapable of infecting SCID mice immunized with anti- $A1 arp^-/vlsE^-$  antibodies (Table 1). This latter result suggests that the anti- $A1 arp^-/vlsE^-$  serum contains antibodies against *B. burgdorferi* surface antigens that are not protected by VlsE.

The *in-vitro*-grown B31-strain-derived spirochetes utilized in the above passive immunization assays might display some surface antigens that would not normally be expressed during host infection and thus may not be typically protected by the presence of VlsE. This could potentially account for the lack of universal protection exhibited by the VlsE. Additionally, the possibility exists that other host-specific surface proteins of *B. burgdorferi* may also be able to protect Arp from host antibodies. For these reasons, we decided to challenge passively immunized mice with “host-adapted” spirochetes via an infected ear tissue transplantation methodology (Rogovskyy and Bankhead, 2013; de Silva

et al., 1998). To do this, *B. burgdorferi*-infected ear biopsy tissue was transplanted via subcutaneous stab incision into passively immunized SCID mice. Similar to the previous experiments utilizing *in-vitro*-grown spirochetes, the results showed that anti-Arp antibodies were able to prevent infection by the host-adapted A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> clone despite the presence of upregulated mammalian host-associated surface proteins in these spirochetes (Table S4). In contrast, the host-adapted A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> spirochetes were able to infect sera-treated mice, thereby providing further support that VlsE specifically functions to protect Arp from host antibodies. Finally, the host-adapted A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> clone was unable to infect mice treated with sera raised against the parent A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> clone (Table S4), again suggesting that VlsE does not universally protect all *B. burgdorferi* antigens.

### Anti-Arp Antibodies Bind *B. burgdorferi* Expressing Arp, but Not to *B. burgdorferi* Expressing Both Arp and VlsE

The VlsE-mediated protection of Arp observed in the murine challenge assays may involve an epitope-shielding mechanism. To test this possibility, immunofluorescence analysis was carried out on intact *B. burgdorferi* cells using Arp antisera. A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> spirochetes could be detected via immunofluorescence using Arp antisera as primary antibodies, confirming the binding of anti-Arp antibodies to Arp epitopes present on the surface of these spirochetes (Figure 2A). Importantly, the anti-Arp antibodies were specific to the Arp antigen, as these antibodies were unable to detect the A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> parent clone lacking both Arp and VlsE. As predicted, A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> spirochetes were undetectable by immunofluorescence using these same antisera (Figure 2A), indicating that VlsE indeed shields Arp epitopes from anti-Arp antibody recognition and binding. To confirm that only surface-expressed proteins were targeted by the anti-Arp antibodies, A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> was probed with antibodies raised against the periplasmic flagellar protein FlaB. Indeed, anti-FlaB antibodies could only access the periplasmic flagellar protein when spirochetes were first permeabilized with methanol (Figure 2B). Finally, all *B. burgdorferi* strains could be detected when A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> antisera were used, implying that not all surface antigens are shielded by VlsE (Figure 3). These results corroborate the findings obtained from the mouse challenge assays (Tables 1 and S4), including those suggesting that VlsE-mediated protection does not encompass all proteins expressed on the *B. burgdorferi* cell surface.

## DISCUSSION

Numerous studies over the years have demonstrated the importance of VlsE antigenic variation for immune evasion and persistence during host infection by the Lyme disease pathogen. However, the question remained how antigenic variation of a single protein could confer protection to *B. burgdorferi* from antibodies that are known to be generated against a large number of proteins expressed on the spirochete cell surface. The studies presented here are a continuation of work by our lab demonstrating the presence of a VlsE-mediated immuneavoidance system that allows for evasion of non-VlsE surface antigens from the host antibody response (Bankhead, 2016; Bankhead and Chaconas, 2007; Rogovskyy and Bankhead, 2013; Rogovskyy et al., 2015).



In the current study, we demonstrate that Arp antisera can prevent infection of mice by *B. burgdorferi* expressing Arp and lacking VlsE, thus corroborating earlier studies suggesting that Arp is an immunodominant protein (Hodzic et al., 2002; Tunev et al., 2011). However, these same antibodies were unable to prevent infection by either *in-vitro*-grown or host-adapted spirochetes expressing both Arp and VlsE, indicating that VlsE protects Arp against host antibodies. Moreover, the results demonstrating that the host-adapted A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> clone was able to successfully infect anti-Arp-sera-treated mice indicate that the protective effects may be specific to VlsE. However, in the absence of another surface-protein-expressing plasmid isogenic to the VlsE-producing plasmid presented in this study, the possibility cannot be ruled out that overexpression of other lipoproteins might also protect Arp. Additional studies will be needed in order to determine whether immune protection of Arp is truly a specific function mediated by VlsE.

The likelihood that the observed immune protection by VlsE is via epitope shielding is demonstrated by the inability of Arp-specific antibodies to bind spirochetes that express VlsE in immunofluorescent assays. One caveat that deserves mention is that the *in vitro* expression levels of both Arp and VlsE are abnormally high in the engineered clones, and whether this has any bearing on how VlsE and Arp interact during infection by wild-type spirochetes is difficult to assess. However, it can be argued that increased expression of Arp would normally be expected to circumvent any potential shielding effects by VlsE. For this reason, we feel that our results strongly argue in favor of VlsE providing protection to Arp given the high expression levels of this protein. An additional caveat is that the A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> spirochetes lack the lp25 plasmid, which is still present in the A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> clone. This plasmid was lost after transformation of cells with pBSV2-*vlsE* but still retains infectivity due to the presence of the *pncA* gene harbored on this same plasmid. Although any effects on the prevention of binding by anti-Arp antibodies cannot be ruled out, we believe this genetic difference is irrelevant due to the specificity in binding of the Arp antisera to the A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> spirochetes in comparison to the parental A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> clone, both of which contain lp25.

Arp is a highly conserved protein (95%–100% identity) among *B. burgdorferi sensu stricto* strains (Imai et al., 2013), which are primarily responsible for cases of Lyme disease in the United States (Heymann and Ellis, 2012). Apart from its role in Lyme disease arthritis (Feng et al., 2003), the biological function of Arp during host infection by *B. burgdorferi* is not currently known. Nevertheless, being a highly conserved protein and an immunodominant antigen, Arp would likely render *B. burgdorferi* amenable to complete elimination if it were not protected by the immune-evasive and antigenically variable VlsE protein. This would also offer a more cost-effective means of immune evasion: devote one protein to evade an adaptive immune response against other important proteins that need to be conserved for better survival of the pathogen.

In summary, we now demonstrate that Arp is shielded by VlsE from host antibodies, providing an explanation as to why anti-Arp antibodies were previously found to be unable to clear spirochetes during murine infection (Barthold et al., 2006; Feng et al., 2003). The findings presented here identify one of potentially multiple proteins that are protected through VlsE-mediated immune evasion and provide direct evidence of epitope shielding by

the VlsE protein. The ability to assay for protection of Arp will now allow for experimental assays aimed at dissecting the mechanistic aspects of VlsE-mediated immune protection. It is also clear that VlsE is not a universal protector against all the anti-borrelial antibodies. Future studies will be necessary to determine how VlsE can sustain *B. burgdorferi* persistence during host infection in spite of the fact that it does not provide protection against all borrelial surface antigens.

## STAR★METHODS

### LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Dr. Troy Bankhead (tbankhead@wsu.edu). All unique/stable reagents generated in this study are available from the Lead Contact without restriction.

### EXPERIMENTAL MODEL AND SUBJECT DETAILS

**B. burgdorferi strains and culture conditions**—Clones described in this study (Table S1) were generated from the B31-A1 strain (Elias et al., 2002). The plasmid profiles of these clones are shown in Figure S3, and comparison among the plasmid profiles in Table S2. All *B. burgdorferi* strains were grown at 35°C under 1.5% CO<sub>2</sub> tension in Barbour-Stoenner-Kelly II (BSK-II) medium supplemented with 6% rabbit serum and appropriate antibiotics as required (gentamicin 100 µg/ml and/or kanamycin 100 µg/ml). Cell densities and growth phase were monitored by dark-field microscopy and enumerated using a Petroff-Hausser counting chamber.

**Mice**—For *in vivo* studies, four to five-week-old male C3H SCID (C3SnSmn.CB17-*Prkdc*<sup>scid</sup>/J, Jackson Laboratory) were subcutaneously inoculated with 100 µl of sera raised either against the A1 *arp*<sup>-</sup>/*vlsE*<sup>-</sup> clone or against recombinant Arp, and then infection with the appropriate clone of *B. burgdorferi* was followed 16 hours later. Clones were passaged no more than two times *in vitro* from frozen glycerol stocks prior to murine challenge. Tissue were collected for spirochete presence or absence as described in Method Details.

For infection of mice via tissue transplantation, 3 mm diameter discs of ear tissue containing host-adapted borrelia were transplanted into the lumbar region of SCID mice. Ear (pinnae) tissues were harvested from SCID mice at 21 days post infection. Mice were anesthetized with isoflurane, and their ears were shaven, disinfected with Betadine Surgical Scrub (Purdue Products, Stamford, CT), and then briefly washed with isopropyl alcohol followed by rinsing with sterile water and dried with sterile gauze. Mice were euthanized to harvest ears, which were cut into 3 mm diameter discs using a biopsy punch tool. The discs were immediately transplanted underneath the skin via a small stab incision in a shaven surgical clean lumbar region. To verify that the tissue explants contained live spirochetes, a piece of 3 mm ear tissue from each mouse was incubated in BSK-II medium supplemented with a mixture of antibiotic and antifungal drugs as described above. The presence or absence of spirochetes in mice that were transplanted with infected tissue was determined by culture of tissues and microscopy as described below.



**Ethics statement**—The experiments on mice were carried out according to the protocols and guidelines approved by American Association for Accreditation of Laboratory Animal Care (AAALAC) and by the Office of Campus Veterinarian at Washington State University (Animal Welfare Assurance A3485–01 and USDA registration number 91-R-002). The animals were housed and maintained in an AAALAC-accredited facility at Washington State University, Pullman, WA. The Washington State University Institutional Animal Care and Use Committee approved the experimental procedures carried out during the current studies.

## METHOD DETAILS

**Generation of Arp- and VlsE-expressing clones**—The *B. burgdorferi* A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> clone was generated by transforming B31-A1 cells with a pBSV2g (Elias et al., 2003) shuttle plasmid containing *arp* gene (corresponding to coordinates 68 to 1605 of lp28–1) and its native promoter (pBSV2g-*arp*). The plasmid also carries *aacC1* gene conferring resistance to gentamicin. The A1 *arp*<sup>+</sup>/*vlsE*<sup>+</sup> clone was generated by transforming the A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> strain with pBSV2 containing *vlsE* and *pncA* (pBSV2-*vlsE*) along with their native promoter sequences. This plasmid was constructed by first cloning *pncA* into the pBSV2 (Stewart et al., 2001) shuttle vector (at NcoI and FseI restriction sites) that harbors a *flaB* promoter-driven kanamycin gene (pBSV2-*pncA*). Next, the *vlsE* gene along with its upstream 93 bp region was amplified using primers containing KpnI and XbaI restriction sites for cloning into above plasmid construct. An additional strain A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> pBSV2-*pncA* was also constructed by transforming A1 *arp*<sup>+</sup>/*vlsE*<sup>-</sup> with pBSV2-*pncA*. All constructed plasmids were confirmed via PCR and DNA sequencing using primers shown in Table S5.

**B. burgdorferi transformation**—*B. burgdorferi* B31-A1 cells were electroporated and cultured as previously described (Bankhead and Chaconas, 2007). DNA from culture-positive wells was extracted using a Wizard Genomic DNA Purification Kit (Promega Corp., Madison, WI), and used for PCR analysis to confirm the presence of the antibiotic-resistance gene and the presence or absence of *arp* and *vlsE* (Figure S4). Naturally occurring plasmid content for each verified transformant was determined by PCR (Figure S3) using plasmid-specific primers as previously described (Bunikis et al., 2011).

**Production of recombinant Arp**—A 941 bp region (from coordinates 525 to 1465) of lp28–1 was PCR amplified (Table S5) and cloned into the pET15b expression vector (Novagen, Madison WI) to introduce a 6X His-tag at the N terminus of Arp. The resulting plasmid was introduced into *E. coli* Rosetta (DE3) pLysS Competent Cells (Novagen). His-tagged Arp expression was induced by adding 1 mM IPTG (Isopropyl β-D-1-thiogalactopyranoside, Novagen) to the *E. coli* culture. The protein was harvested and purified using the Ni-NTA Purification System (ThermoFisher Scientific, Waltham, MA) under native conditions to preserve the three-dimensional structure of the protein. The purified protein content in each fraction was determined by Coomassie Plus Assay kit (ThermoFisher Scientific, Rockford, IL).

**Production of Arp-specific antibodies**—Anti-Arp antibodies were raised in C3H mice (Jackson Laboratory, Bar Harbor, ME) by inoculating the mice with purified recombinant

Arp as a water-in-oil emulsion formulation. A 0.5 mL volume of aqueous Arp antigen was emulsified in 0.5 mL of Titermax Gold (Sigma Aldrich, St. Louis, MO) adjuvant using a two-syringe, 3-way stopcock method. Each mouse was inoculated subcutaneously with 100  $\mu$ l (36  $\mu$ g protein) of the emulsion in four divided doses at four different sites. A booster dose of Arp antigen (total 12  $\mu$ g) was administered in exactly in the same manner 28 days after the initial inoculation. Blood was collected (through cardiac puncture) after 2 weeks of booster dose and centrifuged at 6,000 $\times$ *g* for 12 minutes at 4°C to separate serum from blood cellular components. Anti-Arp antibodies were isolated from serum using Melon Gel IgG Purification kit (Thermo Scientific).

**Generation of antisera against A1arp<sup>-</sup>/vlsE<sup>-</sup>, A1arp<sup>+</sup>/vlsE<sup>-</sup>, and A1arp<sup>+</sup>/vlsE<sup>+</sup> clones**—Antisera was raised in C3H mice (C3H/HeJ, The Jackson Laboratory) for animal challenge experiments and western blot analysis, against A1arp<sup>-</sup>/vlsE<sup>-</sup>, A1arp<sup>+</sup>/vlsE<sup>-</sup>, and A1arp<sup>+</sup>/vlsE<sup>+</sup> clones. Because these clones either lack VlsE (A1arp<sup>-</sup>/vlsE<sup>-</sup> and A1arp<sup>+</sup>/vlsE<sup>-</sup>) or possess a non-variable VlsE (A1arp<sup>+</sup>/vlsE<sup>+</sup>), spirochetes are cleared within three weeks by immunocompetent mice. To generate a better immune response, C3H mice were infected via subcutaneous needle inoculation with a higher dose of spirochetes (10<sup>7</sup>–10<sup>8</sup> total organisms per mouse), and the mice were re-inoculated every two weeks for a total of three inoculations. Blood was collected after two weeks of the last infection and serum was separated by centrifugation. Sera were pooled from four to five mice for use in various subsequent experiments.

**Tissue collection for spirochete detection**—The presence or absence of spirochetes was determined from blood samples (50  $\mu$ l via saphenous vein) collected 7 days post infection, or from tissue samples (ear, heart, joint and urinary bladder) harvested at 28 days post infection. Blood and tissues were incubated in BSK-II medium supplemented with a mixture of antibiotic and antifungal drugs (0.02 mg/ml phosphomycin, 0.05 mg/ml rifampin, and 2.5  $\mu$ g/ml amphotericin B) to prevent the growth of contaminating bacteria and fungi. The cultures were examined by dark field microscopy for the presence or absence of spirochetes following four to seven days of incubation. The tissues from individual mice were also incubated in BSK-II medium containing gentamicin (100  $\mu$ g/ml) or kanamycin (100  $\mu$ g/ml) to ensure that the recovered *B. burgdorferi* clones had not lost the plasmid vector containing arp and vlsE genes during the infection period. Presence of arp and vlsE genes in the recovered bacteria was further confirmed by PCR.

**Western blot analysis**—Late log-phase cultures of *B. burgdorferi* were used in western blot. The number of spirochetes in a culture were determined using Petroff-Hausser counting chamber. The bacteria were then centrifuged, and the resulting pellet lysed by boiling in Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA, USA) for 10 min. The volume of sample buffer representing equal amounts of lysed bacteria (approximately 10<sup>5</sup> lysed cells) from each sample was loaded on each lane of Any Kd Mini-ProteanTGX Stain-Free precast polyacrylamide gels (Bio-Rad Laboratories). After electrophoresis, the proteins were transferred to a nitrocellulose membrane of pore size 0.45  $\mu$ m (Bio-Rad Laboratories). The membrane was blocked with nonfat dry milk to prevent non-specific binding of antibodies, followed by incubation in primary and then horseradish peroxidase-conjugated anti-mouse

goat or anti-rabbit donkey secondary antibody (Abcam, Cambridge, MA) according to the method described previously (Casselli et al., 2012). The bands were visualized in presence of chemiluminescent substrate (Clarity Western ECL, Bio-Rad Laboratories) using ChemiDoc digital imager (Bio-Rad Laboratories). As primary antibodies, anti-Arp and anti-VlsE antibodies (Rockland, Limerick, PA) were used at 1:1,000 fold and serum at 1:2,000 fold dilution. Secondary antibody was used at 1:1,000fold dilution. Proteinase K treatment on the various intact *B. burgdorferi* clones was carried out as described previously (Norris et al., 1992).

**Extraction of membrane proteins**—Membrane proteins were extracted from  $A1arp^-/vlsE^-$ ,  $A1arp^+/vlsE^-$ ,  $A1arp^-/vlsE^+$  and  $A1arp^+/vlsE^+$  strains using the nonionic detergent, Triton X-114 (Sigma Aldrich), according to previously described protocols (Benoit et al., 2011; Brandt et al., 1990; Wood et al., 2013). Approximately  $10^9$  cells from each strain were pelleted by centrifugation and the pellet washed three times in PBS. After washing, the pellet was suspended in Triton X-114 detergent (2% vol/vol in PBS), and then incubated overnight at 4°C with rocking to solubilize the membrane lipoproteins in the detergent. The insoluble material containing protoplasmic cylinders were pelleted by centrifugation at  $15000 \times g$  for 30 min at 4°C. The supernatant was removed, and the pellet discarded. To phase separate the lipoprotein-containing detergent phase from the aqueous phase, the supernatant was incubated at 37°C for 15 min, followed by centrifugation at  $15000 \times g$  at room temperature for 10 minutes. The detergent phase was carefully removed, and both the detergent phase as well as the aqueous phase were washed three times in PBS and Triton X-114 (2% final concentration in aqueous phase fraction), respectively. Proteins in the detergent and aqueous phases were precipitated by cold acetone (−20°C) and pelleted by centrifugation. The supernatant was decanted, and the pellet was suspended in 1x Laemmli sample buffer (Bio-Rad Laboratories). The protein content was determined by the RC DC Protein Assay Kit II (Bio-Rad Laboratories). The proteins were run on Any Kd Mini-ProteanTGX precast polyacrylamide gels (Bio-Rad Laboratories) for staining with Oriole Fluorescent Gel stain (Bio-Rad Laboratories). To probe for membrane localization of Arp and VlsE in detergent phase, immunoblotting was carried out using anti-Arp and Anti-VlsE antibodies (Rockland). To ensure that detergent phase contained only membrane proteins and aqueous phase only water-soluble proteins, antiBosR antibodies (General Bioscience, Brisbane, CA) were used to confirm the presence of BosR (cytosolic protein) in the aqueous fraction, but absence in the detergent fraction.

**Flow Cytometry Assay**—For flow cytometry experiments, approximately  $10^7$  spirochetes from each strain were incubated in 1% paraformaldehyde for 10 minutes to minimize damage to spirochetes in multiple washing steps down stream. The spirochetes were subsequently washed with and then resuspended in HEPES-buffered Tyrode's Solution (HTS) (Boston Bioproducts, Ashland, MA). The bacterial suspension was incubated with anti-Arp or anti-VlsE antibodies (1:50 fold dilution) for one hour at 4°C. The cells were again washed with and then re-suspended HTS for incubation in Alexa Fluor 647-labeled donkey anti-mouse IgG (ThermoFisher Scientific, Rockford, IL) or donkey anti-rabbit IgG (Abcam, Cambridge, MA) antibodies (1:200 fold dilution) for 30 minutes. The cells were washed as before with HTS, followed by fixing in 1% paraformaldehyde. After fixation, the

cells were washed with double distilled water to remove phosphates, which interfere with Syto 9 dye (subsequent step). The cell suspension in double distilled water was incubated in 10  $\mu$ M Syto 9 (Life Technologies Corporation, Eugene, OR) for 30 minutes. Syto 9 staining was carried out to distinguish spirochetes from noise and debris in the flow cytometric analysis. Mouse antibodies obtained from uninfected (Arp- and VlsE-antibody free) C3H mice were used as isotypic controls. Flow cytometric analysis was performed using a Guava EasyCyte flow cytometer (Millipore), and data were acquired using InCyte (GuavaSoft 3.1.1). A minimum of 30,000 events were collected for each bacterial sample. After acquisition, results were analyzed in FCS Express version 6 (DeNovo Software). Expression of Arp or VlsE on the surface of spirochetes is presented using histograms, where a log<sub>10</sub> scale was used on the x axis and a linear scale on the y axis.

**Immunofluorescence Assay**—Immunofluorescence was carried out with some modifications of previously described protocols (Bryksin et al., 2010; Mulay et al., 2007; Zhang et al., 2011). Spirochetes were grown to late log-phase, centrifuged to remove the medium and washed three times in HEPES-buffered Tyrode's Solution (HTS) (Boston Bioproducts) to remove residual medium components including serum. The cell pellet containing approximately  $10^7$  spirochetes was re-suspended in HTS. The spirochetes were incubated in primary antibodies (1:50 fold dilution) for one hour at 35°C. The antibodies used were mouse anti-Arp and anti-*A1arp*<sup>-</sup>/*vlsE*<sup>-</sup> antisera, and rabbit anti-FlaB antibodies (Rockland). After incubation, the cells were washed with HTS, and then resuspended in the same buffer. Ten microliters of this suspension were deposited on positively charged glass slides (Probe On Pulse, Fisher Scientific), dried, and free sites on the slide were blocked by casein-based blocking buffer (casein in PBS buffer with Tween 20, Abcam). This was followed by incubating the spirochetes in either Alexa Fluor 647-labeled donkey anti-mouse IgG (ThermoFisher Scientific, Rockford, IL) or donkey anti-rabbit IgG (Abcam, Cambridge, MA) antibodies (1:500 fold dilution in blocking buffer), depending upon the species of origin of the primary antibody. The slides were again washed in PBS, followed by fixing of spirochetes in 4% paraformaldehyde for 10 min. The slides were finally mounted with coverslips, using Prolong Gold Antefade mountant containing DAPI (ThermoFisher Scientific). The bacteria were imaged with appropriate wavelength laser light using Leica SP8 confocal microscope (Leica Microsystems Inc., Deerfield, IL).

To ascertain that the spirochete proteins of our interest are targeted by the primary antibodies only when located on the cell surface, we used antibody anti-FlaB antibodies (targets periplasmic FlaB) as described above. That periplasmic protein FlaB can be accessed by anti-FlaB antibodies only after membrane is permeabilized, five microliters of bacteria were also deposited on positively charged slides, dried and then fixed in methanol for 20 minutes. The slides were washed in PBS (pH 7.4) and free sites were blocked by the casein-based blocking buffer (Abcam). The spirochetes were incubated with anti-FlaB antibody (1:50 dilution) for one hour, then washed in PBS before being incubating in Alexa Fluor 647-labeled donkey anti-mouse IgG (ThermoFisher Scientific, Rockford, IL) at room temperature for one hour. The slides were again washed in PBS and were mounted with coverslips, using Prolong Gold Antefade mountant containing DAPI (ThermoFisher Scientific) and visualized using confocal microscopy as above.

## QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical parameters including statistical significance is indicated in the table footnote. To test overall statistically significant difference across all treatment groups, Fisher's exact test was used, while Bonferroni correction was used for differences between groups.  $p < 0.05$  was considered statistically significant difference.

## DATA AND CODE AVAILABILITY

The published article contains most of the data; a request for any raw data can be made to the lead contact.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## ACKNOWLEDGMENTS

This research was supported by a grant from the National Institutes of Health (R01 AI108704). We are particularly thankful to Dr. Reginaldo Bastos of the USDA-ARS unit at Washington State University for help with flow cytometry experiments. The authors would like to thank Michael Crowley, Shao-Yeh Lu, Jessica Wong, and Youki Yamasaki for providing helpful comments regarding the manuscript. The authors also thank the Call lab for generous help with some chemicals and reagents used during this work.

## REFERENCES

- Bankhead T (2016). Role of the VlsE lipoprotein in immune avoidance by the Lyme disease spirochete *Borrelia burgdorferi*. *For. Immunopathol. Dis. Therap.* 7, 191–204.
- Bankhead T, and Chaconas G (2007). The role of VlsE antigenic variation in the Lyme disease spirochete: persistence through a mechanism that differs from other pathogens. *Mol. Microbiol.* 65, 1547–1558. [PubMed: 17714442]
- Barthold SW, Hodzic E, Tunev S, and Feng S (2006). Antibody-mediated disease remission in the mouse model of lyme borreliosis. *Infect. Immun.* 74, 4817–4825. [PubMed: 16861670]
- Benoit VM, Fischer JR, Lin YP, Parveen N, and Leong JM (2011). Allelic variation of the Lyme disease spirochete adhesin DbpA influences spirochetal binding to decorin, dermatan sulfate, and mammalian cells. *Infect. Immun.* 79, 3501–3509. [PubMed: 21708995]
- Bouchard C, Leonard E, Koffi JK, Pelcat Y, Peregrine A, Chilton N, Rochon K, Lysyk T, Lindsay LR, and Ogden NH (2015). The increasing risk of Lyme disease in Canada. *Can. Vet. J.* 56, 693–699. [PubMed: 26130829]
- Brandt ME, Riley BS, Radolf JD, and Norgard MV (1990). Immunogenic integral membrane proteins of *Borrelia burgdorferi* are lipoproteins. *Infect. Immun.* 58, 983–991. [PubMed: 2318538]
- Bryksin AV, Tomova A, Godfrey HP, and Cabello FC (2010). BmpA is a surface-exposed outer-membrane protein of *Borrelia burgdorferi*. *FEMS Microbiol. Lett.* 309, 77–83. [PubMed: 20546313]
- Bunikis I, Kutschan-Bunikis S, Bonde M, and Bergström S (2011). Multiplex PCR as a tool for validating plasmid content of *Borrelia burgdorferi*. *J. Microbiol. Methods* 86, 243–247. [PubMed: 21605603]
- Casselli T, Tourand Y, and Bankhead T (2012). Altered murine tissue colonization by *Borrelia burgdorferi* following targeted deletion of linear plasmid 17-carried genes. *Infect. Immun.* 80, 1773–1782. [PubMed: 22354033]
- CDC, 2019 Reported cases of Lyme disease by year–United States, 2009–2018. URL: <https://www.cdc.gov/lyme/stats/tables.html> Centers for Disease Control and Prevention.
- CDC, 2019 Clinical manifestations of confirmed Lyme disease cases–United States, 2008–2018. URL: <https://www.cdc.gov/lyme/stats/graphs.html> Centers for Disease Control and Prevention.


- de Silva AM, Fikrig E, Hodzic E, Kantor FS, Telford SR 3rd, and Barthold SW (1998). Immune evasion by tickborne and host-adapted *Borrelia burgdorferi*. *J. Infect. Dis.* 177, 395–400. [PubMed: 9466527]
- Elias AF, Stewart PE, Grimm D, Caimano MJ, Eggers CH, Tilly K, Bono JL, Akins DR, Radolf JD, Schwan TG, and Rosa P (2002). Clonal polymorphism of *Borrelia burgdorferi* strain B31 MI: implications for mutagenesis in an infectious strain background. *Infect. Immun.* 70, 2139–2150. [PubMed: 11895980]
- Elias AF, Bono JL, Kupko JJ 3rd, Stewart PE, Krum JG, and Rosa PA (2003). New antibiotic resistance cassettes suitable for genetic studies in *Borrelia burgdorferi*. *J. Mol. Microbiol. Biotechnol.* 6, 29–40. [PubMed: 14593251]
- Feng S, Hodzic E, and Barthold SW (2000). Lyme arthritis resolution with antiserum to a 37-kilodalton *Borrelia burgdorferi* protein. *Infect. Immun.* 68, 4169–4173. [PubMed: 10858233]
- Feng S, Hodzic E, Freet K, and Barthold SW (2003). Immunogenicity of *Borrelia burgdorferi* arthritis-related protein. *Infect. Immun.* 71, 7211–7214. [PubMed: 14638819]
- Grimm D, Eggers CH, Caimano MJ, Tilly K, Stewart PE, Elias AF, Radolf JD, and Rosa PA (2004). Experimental assessment of the roles of linear plasmids lp25 and lp28–1 of *Borrelia burgdorferi* throughout the infectious cycle. *Infect. Immun.* 72, 5938–5946. [PubMed: 15385497]
- Heymann WR, and Ellis DL (2012). *Borrelia burgdorferi* Infections in the United States. *J. Clin. Aesthet. Dermatol.* 5, 18–28.
- Hinckley AF, Connally NP, Meek JI, Johnson BJ, Kemperman MM, Feldman KA, White JL, and Mead PS (2014). Lyme disease testing by large commercial laboratories in the United States. *Clin. Infect. Dis.* 59, 676–681. [PubMed: 24879782]
- Hodzic E, Feng S, Freet KJ, Borjesson DL, and Barthold SW (2002). *Borrelia burgdorferi* population kinetics and selected gene expression at the host-vector interface. *Infect. Immun.* 70, 3382–3388. [PubMed: 12065476]
- Hove PR, Haldorson GJ, Magunda F, and Bankhead T (2014). Presence of Arp specifically contributes to joint tissue edema associated with early-onset Lyme arthritis. *Infect. Immun.* 82, 43–51. [PubMed: 24101694]
- Hyde JA (2017). *Borrelia burgdorferi* keeps moving and carries on: a review of borrelial dissemination and invasion. *Front. Immunol.* 8, 114. [PubMed: 28270812]
- Imai D, Holden K, Velazquez EM, Feng S, Hodzic E, and Barthold SW (2013). Influence of arthritis-related protein (BBF01) on infectivity of *Borrelia burgdorferi* B31. *BMC Microbiol.* 13, 100. [PubMed: 23651628]
- Johnson KO, Nelder MP, Russell C, Li Y, Badiani T, Sander B, Sider D, and Patel SN (2018). Clinical manifestations of reported Lyme disease cases in Ontario, Canada: 2005–2014. *PLoS ONE* 13, e0198509. [PubMed: 29856831]
- Kuehn BM (2013). CDC estimates 300,000 US cases of Lyme disease annually. *JAMA* 310, 1110. [PubMed: 24045727]
- Lawrenz MB, Wooten RM, and Norris SJ (2004). Effects of *vlsE* complementation on the infectivity of *Borrelia burgdorferi* lacking the linear plasmid lp28–1. *Infect. Immun.* 72, 6577–6585. [PubMed: 15501789]
- Liang FT, Jacobs MB, Bowers LC, and Philipp MT (2002). An immune evasion mechanism for spirochetal persistence in Lyme borreliosis. *J. Exp. Med.* 195, 415–422. [PubMed: 11854355]
- Liang FT, Yan J, Mbow ML, Sviat SL, Gilmore RD, Mamula M, and Fikrig E (2004). *Borrelia burgdorferi* changes its surface antigenic expression in response to host immune responses. *Infect. Immun.* 72, 5759–5767. [PubMed: 15385475]
- Mulay V, Caimano MJ, Liveris D, Desrosiers DC, Radolf JD, and Schwartz I (2007). *Borrelia burgdorferi* BBA74, a periplasmic protein associated with the outer membrane, lacks porin-like properties. *J. Bacteriol.* 189, 2063–2068. [PubMed: 17189354]
- Murray TS, and Shapiro ED (2010). Lyme disease. *Clin. Lab. Med.* 30, 311–328. [PubMed: 20513553]
- Norris SJ (2006). Antigenic variation with a twist—the *Borrelia* story. *Mol. Microbiol.* 60, 1319–1322. [PubMed: 16796669]



- Norris SJ, Carter CJ, Howell JK, and Barbour AG (1992). Low-passage-associated proteins of *Borrelia burgdorferi* B31: characterization and molecular cloning of OspD, a surface-exposed, plasmid-encoded lipoprotein. *Infect. Immun.* 60, 4662–4672. [PubMed: 1398980]
- Palmer GH, Bankhead T, and Lukehart SA (2009). ‘Nothing is permanent but change’- antigenic variation in persistent bacterial pathogens. *Cell. Microbiol.* 11, 1697–1705. [PubMed: 19709057]
- Philipp MT, Bowers LC, Fawcett PT, Jacobs MB, Liang FT, Marques AR, Mitchell PD, Purcell JE, Ratterree MS, and Straubinger RK (2001). Antibody response to IR6, a conserved immunodominant region of the VlsE lipoprotein, wanes rapidly after antibiotic treatment of *Borrelia burgdorferi* infection in experimental animals and in humans. *J. Infect. Dis.* 184, 870–878. [PubMed: 11550127]
- Rogovskyy AS, and Bankhead T (2013). Variable VlsE is critical for host reinfection by the Lyme disease spirochete. *PLoS ONE* 8, e61226. [PubMed: 23593438]
- Rogovskyy AS, and Bankhead T (2014). Bacterial heterogeneity is a requirement for host superinfection by the Lyme disease spirochete. *Infect. Immun.* 82, 4542–4552. [PubMed: 25114120]
- Rogovskyy AS, Casselli T, Tourand Y, Jones CR, Owen JP, Mason KL, Scoles GA, and Bankhead T (2015). Evaluation of the importance of VlsE antigenic variation for the enzootic cycle of *Borrelia burgdorferi*. *PLoS ONE* 10, e0124268. [PubMed: 25893989]
- Stanek G, Wormser GP, Gray J, and Strle F (2012). Lyme borreliosis. *Lancet* 379, 461–473. [PubMed: 21903253]
- Steere AC, Strle F, Wormser GP, Hu LT, Branda JA, Hovius JW, Li X, and Mead PS (2016). Lyme borreliosis. *Nat. Rev. Dis. Primers* 2, 16090. [PubMed: 27976670]
- Stewart PE, Thalken R, Bono JL, and Rosa P (2001). Isolation of a circular plasmid region sufficient for autonomous replication and transformation of infectious *Borrelia burgdorferi*. *Mol. Microbiol.* 39, 714–721. [PubMed: 11169111]
- Tuney SS, Hastey CJ, Hodzic E, Feng S, Barthold SW, and Baumgarth N (2011). Lymphadenopathy during Lyme borreliosis is caused by spirochete migration-induced specific B cell activation. *PLoS Pathog.* 7, e1002066. [PubMed: 21637808]
- Verhey TB, Castellanos M, and Chaconas G (2018a). Analysis of recombinational switching at the antigenic variation locus of the Lyme spirochete using a novel PacBio sequencing pipeline. *Mol. Microbiol.* 108, 461. [PubMed: 29740915]
- Verhey TB, Castellanos M, and Chaconas G (2018b). Antigenic variation in the Lyme spirochete: insights into recombinational switching with a suggested role for error-prone repair. *Cell Rep.* 23, 2595–2605. [PubMed: 29847791]
- Wood E, Tamborero S, Mingarro I, and Esteve-Gassent MD (2013). BB0172, a *Borrelia burgdorferi* outer membrane protein that binds integrin  $\alpha 3\beta 1$ . *J. Bacteriol.* 195, 3320–3330. [PubMed: 23687274]
- Wright WF, Riedel DJ, Talwani R, and Gilliam BL (2012). Diagnosis and management of Lyme disease. *Am. Fam. Physician* 85, 1086–1093. [PubMed: 22962880]
- Zhang JR, and Norris SJ (1998). Kinetics and *in vivo* induction of genetic variation of *vlsE* in *Borrelia burgdorferi*. *Infect. Immun.* 66, 3689–3697. [PubMed: 9673250]
- Zhang JR, Hardham JM, Barbour AG, and Norris SJ (1997). Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. *Cell* 89, 275–285. [PubMed: 9108482]
- Zhang L, Zhang Y, Adusumilli S, Liu L, Narasimhan S, Dai J, Zhao YO, and Fikrig E (2011). Molecular interactions that enable movement of the Lyme disease agent from the tick gut into the hemolymph. *PLoS Pathog.* 7, e1002079. [PubMed: 21695244]

**Highlights**

- Protection of a *B. burgdorferi* surface antigen from host antibodies is mediated by the antigenically variable VlsE lipoprotein
- Evidence supports a mechanism of epitope shielding by VlsE
- VlsE is not a universal protector against all anti-borrelial antibodies



**Figure 1. *In Vitro* and *In Vivo* Expression of Both Arp and VlsE and Their Surface Localization by *B. burgdorferi* Clones**

(A and B) Western blots demonstrating *in vitro* VlsE and Arp expression by the wild-type B31-A3 strain and B31-A1 derived clones transformed with circular plasmid vectors carrying *vlsE* and *arp*. Recombinant Arp (rArp) and VlsE (rVlsE-MBP) served as positive controls. The blots were probed with either (A) anti-VlsE (αVlsE) or (B) anti-Arp antibodies (αArp).

(C and D) Cell-surface localization of VlsE and Arp in clones treated with or without proteinase K (pk). Western blot of (C) A1arp<sup>+</sup>/vlsE<sup>+</sup> and A1arp<sup>-</sup>/vlsE<sup>+</sup> cell lysates probed

with  $\alpha$ VlsE antibodies and (D) A1  $arp^+/vlsE^+$  and A1  $arp^+/vlsE^-$  cell lysates probed with  $\alpha$ Arp antibodies are shown.

(E–G) Membrane localization of VlsE and Arp. The membrane lipoproteins (M) were separated in Triton X-114 detergent phase and non-membrane proteins (N) in aqueous phase.

(E and F) Both the detergent and the aqueous phase proteins were probed for the presence of (E) VlsE and (F) Arp.


(G) The cytosolic BosR protein was probed to ascertain proper phase separation of detergent and aqueous phase proteins.

(H) Flow cytometric analysis of Arp expression in A1  $arp^+/vlsE^-$  strain, which harbors an *arp*-expressing plasmid (pBSV2g-*arp*), and a control strain (A1  $arp^+/vlsE^-$  pBSV2-*pncA*) that contains an additional plasmid, pBSV2-*pncA*.

(I and J) *In vivo* expression of VlsE and Arp. *In vivo* expression of (I) VlsE and (J) Arp was confirmed via western blot analysis of A1  $arp^-/vlsE^+$  and A1  $arp^+/vlsE^-$  cell lysates probed with sera raised against A1  $arp^+/vlsE^+$  spirochetes.

(K) *In vivo* expression of Arp by A1  $arp^+/vlsE^-$  spirochetes was confirmed by probing A1  $arp^+/vlsE^-$  cell lysate with sera raised against the A1  $arp^+/vlsE^-$  clone. (Higher amounts of rArp have been loaded in the control lane, hence the brighter band.)

(L) Western blot of cell lysates of A1  $arp^-/vlsE^+$ , A1  $arp^+/vlsE^-$ , and A1  $arp^-/vlsE^-$  probed with A1  $arp^-/vlsE^-$  antisera served as a control for specificity of Arp- and VlsE-specific antibodies in the antisera raised against A1  $arp^+/vlsE^+$  and A1  $arp^+/vlsE^-$  clones. Numbers on the left correspond to approximate molecular weight in kilodaltons. Sera was pooled from multiple mice, and similar dilutions of sera were used in each panel.




**Figure 2. Anti-Arp Antibodies Bind to *B. burgdorferi* Expressing Arp, but Not to *B. burgdorferi* Expressing Both Arp and VlsE**

(A) For immunofluorescence assays, Arp antisera were used as a source of primary antibodies and Alexa-Fluor-647-labeled immunoglobulin G (IgG) as a secondary antibody. DAPI was used as a DNA stain to image the bacteria not bound by primary antibody and thus undetectable using the Alexa Fluor 647 detection channel. Clone names are shown on the left. Rows are the confocal images of the same clone taken in the same focal plane, while columns are arranged by detection channel. Images taken in DAPI and Alexa Fluor 647 channels are merged and shown in the third column. Anti-Arp antibodies could detect spirochetes expressing Arp alone (A1arp<sup>+</sup>/vlsE<sup>-</sup> clone, first row, first image), but not those

that express both Arp and VlsE (*A1arp<sup>+</sup>/vlsE<sup>+</sup>* clone, second row, first image). The clone in the bottom row (*A1arp<sup>-</sup>/vlsE<sup>-</sup>*) lacks both Arp and VlsE proteins and serves as a control for nonspecific Arp antibody binding.

(B) *A1arp<sup>+</sup>/vlsE<sup>+</sup>* spirochetes were probed with anti-FlaB antibodies ( $\alpha$ FlaB) to verify outer membrane integrity during immunofluorescence. The anti-FlaB antibodies could access the periplasmic flagellar protein only when permeabilized with methanol first (bottom row). Each immunofluorescence assay was conducted three times with two independent sets of clones. The scale bar represents 50  $\mu$ m. meth. fix., methanol fixation.





**Figure 3. VlsE Does Not Shield All Surface Antigens from Anti-borrelial Antibodies**

Immunofluorescence experiments using *A1arp<sup>-</sup>/vlsE<sup>-</sup>* antisera as primary antibodies and Alexa-Fluor-647-labeled IgG as secondary antibody. DAPI was used as a DNA stain. Clone names are shown on the left. Rows are the confocal images of the same clone taken in the same focal plane. Images taken in DAPI and Alexa Fluor 647 channels are merged and shown in the third column. Whole-cell anti-borrelial antibodies could easily detect spirochetes whether VlsE is present (*A1arp<sup>+</sup>/vlsE<sup>+</sup>* clone, second row, first image) or not (*A1arp<sup>+</sup>/vlsE<sup>-</sup>* clone, first row, first image and *A1arp<sup>-</sup>/vlsE<sup>-</sup>* clone, third row, first image), indicating that VlsE is unable to shield all the surface proteins against host antibodies. Each immunofluorescence assay was conducted three times with two independent sets of clones. The scale bar represents 50  $\mu$ m.

**Table 1.**

Arp-Specific Antiserum Prevents Infection by *B. burgdorferi* Expressing Arp, but Not by *B. burgdorferi* Expressing Both Arp and VlsE

Antiserum Treatment	Infecting Clone <sup>a</sup>			p Value <sup>b</sup>
	A1arp <sup>+</sup> /vlsE <sup>-</sup>	A1arp <sup>+</sup> /vlsE <sup>+</sup>	A1arp <sup>-</sup> /vlsE <sup>-</sup>	
Arp antisera	2/9*	9/9	8/9	0.0009
A1arp <sup>-</sup> /vlsE <sup>-</sup> antisera	0/6	1/6	0/6	1.0000
Non-immune sera	7/9	6/6	6/6	0.4857

<sup>a</sup>The table shows the proportion of mice (infected/total) successfully infected by *B. burgdorferi* clones after passive immunization with sera shown in the first column. An animal was considered successfully infected if spirochetes were detected from any of the tissues, including ears, heart, bladder, or joints, at 28 days post-challenge.

<sup>b</sup>p values were calculated using Fisher's exact test (last column) to examine whether a statistically significant difference exists across all groups (proportions), while Bonferroni correction was applied to test which exact group differs from another.

\*Significant at  $p < 0.05$  after applying Bonferroni correction for multiple comparisons between groups.

## KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Alexa Fluor 647 Anti-mouse IgG	Thermo Fisher Scientific	Cat# A-31571; RRID:AB_162542
Alexa Fluor 647 Anti-Rabbit IgG	Abcam	Cat# ab150075; RRID:AB_2752244
Anti-A1 <i>arp</i> <sup>-</sup> / <i>vlsE</i> <sup>-</sup>	This paper	N/A
Anti-A1 <i>arp</i> <sup>+</sup> / <i>vlsE</i> <sup>-</sup>	This paper	N/A
Anti-A1 <i>arp</i> <sup>+</sup> / <i>vlsE</i> <sup>+</sup>	This paper	N/A
Anti-Arp antibody	This paper	N/A
Anti-BosR IgG	General Biosciences	Cat# AB76001-200; Clone 2F9-D2.
Anti-FlaB antibody	Rockland	Cat# 200-401-C14; RRID:AB_10703395
Anti-mouse IgG	Abcam	Cat# ab6789; RRID:AB_955439)
Anti-rabbit IgG	Abcam	Cat# ab6802; RRID:AB_955445
Anti-VlsE IgG	Rockland	Cat# 200-401-C33; RRID:AB_10924424
Bacterial and Virus Strains		
<i>B. burgdorferi</i> A1 <i>arp</i> <sup>-</sup> / <i>vlsE</i> <sup>+</sup>	This paper	N/A
<i>B. burgdorferi</i> A1 <i>arp</i> <sup>+</sup> / <i>vlsE</i> <sup>-</sup>	This paper	N/A
<i>B. burgdorferi</i> A1 <i>arp</i> <sup>+</sup> / <i>vlsE</i> <sup>+</sup>	This paper	N/A
<i>B. burgdorferi</i> A1 <i>arp</i> <sup>+</sup> / <i>vlsE</i> <sup>-</sup> pBSV2- <i>pncA</i>	This paper	N/A
<i>B. burgdorferi</i> B31-A1 (A1 <i>arp</i> <sup>-</sup> / <i>vlsE</i> <sup>-</sup> )	Elias et al., 2002	N/A
<i>B. burgdorferi</i> B31-A3	Elias et al., 2002	N/A
<i>E. coli</i> Rosetta (DE3) pLysS	Novagen	Cat# 70956
Chemicals, Peptides, and Recombinant Proteins		
Amphotericin B	Sigma	Cat# A9528; CAS: 1397-89-3
Betadine Surgical Scrub	Purdue Products	Cat# 516163
Blocking buffer	Abcam	Cat# ab126587
Clarity Western ECL	Bio-Rad Laboratories	Cat# 170-5060
Gentamycin	Sigma	Cat# G1264; CAS: 1405-41-0
Isopropyl β-D-1-thiogalactopyranoside	Novagen	Cat# 70527-3; CAS: 367-93-1
Kanamycin	Sigma	Cat# K1377; CAS: 25389-94-0
Methanol	Sigma	Cat# 34860
Oriole Fluorescent Gel Stain	Bio-Rad Laboratories	Cat# 1610496;
Phosphomycin	Sigma	Cat# P5369;
Prolong Gold Antefade	Thermofisher Scientific	Cat# P36941
Rifampicin	Sigma	Cat# R3501; CAS: 13292-46-1
Syto 9	Thermofisher Scientific	Cat# S34854
Titermax Gold	Sigma	Cat# T2684
Triton X-114	Sigma	Cat# X-114; CAS: 9036-19-5
Tyrode's Solution	Boston Bioproducts	Cat# PY-921

REAGENT or RESOURCE	SOURCE	IDENTIFIER
VlsE Control Protein	Rockland	Cat# 000-001-C33
Critical Commercial Assays		
Coomsie Plus Assay Kit	ThermoFisher Scientific	Cat# 23236
Melon Gel IgG Purification Kit	ThermoScientific	Cat# P145206
Ni-NTA Purification System	ThermoFisher Scientific	Cat# K95001
Wizard Genomic DNA Purification Kit	Promega	Cat# A1120,
Experimental Models: Organisms/Strains		
Mouse: C3H/HeJ	The Jackson Laboratory	Stock# 000659; RRID:IMSR_JAX:000659
Mouse: C3SnSmn.CB17-Prkdescid/J	The Jackson Laboratory	Stock# 001131; RRID:IMSR_JAX:001131
Oligonucleotides		
Table S3		
Recombinant DNA		
pBSV2	Stewart et al., 2001	N/A
pBSV2g	Elias et al., 2003	N/A
pBSV2g- <i>arp</i>	This paper	N/A
pBSV2- <i>pncA</i>	This paper	N/A
pBSV2- <i>vlsE</i>	This paper	N/A
Software and Algorithms		
FCS Express version 6	DeNovo Software	<a href="https://denovosoftware.com/installation-instructions/installing-previous-versions/">https://denovosoftware.com/installation-instructions/installing-previous-versions/</a>
InCyte (GuavaSoft 3.1.1).	Luminex Corporation	<a href="https://www.luminexcorp.com/guava-easycyte-software/">https://www.luminexcorp.com/guava-easycyte-software/</a>
Other		
ChemiDoc Touch Imaging System	Bio-Rad Laboratories	<a href="https://www.bio-rad.com/en-us/category/chemidoc-imaging-systems?ID&amp;equals;NINJ0Z15">https://www.bio-rad.com/en-us/category/chemidoc-imaging-systems?ID&amp;equals;NINJ0Z15</a>
Guava EasyCyte 8HT Flow Cytometry	Millipore	<a href="https://expert.cheekyscientist.com/reviews-section/milliporeguava-easycyte-8-10ht/">https://expert.cheekyscientist.com/reviews-section/milliporeguava-easycyte-8-10ht/</a>
Leica TCS SP8 Confocal system	Leica	<a href="https://www.leica-microsystems.com/">https://www.leica-microsystems.com/</a>
Nitrocellulose Membrane	Bio-Rad Laboratories	Cat# 1620215
Probe On Plus Slides	Fisher Scientific	Cat# 22-230-900